SYNGENE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | SYNGENE | Market Cap | 18,539 Cr. | Current Price | 460 ₹ | High / Low | 729 ₹ |
| Stock P/E | 51.3 | Book Value | 117 ₹ | Dividend Yield | 0.27 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 453 ₹ | DMA 200 | 537 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 52.4 | MACD | 7.60 | Volume | 12,87,052 | Avg Vol 1Wk | 7,04,882 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -6.09 | Debt to equity | 0.04 |
| 52w Index | 23.0 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 39.8 |
📊 SYNGENE shows moderate momentum for intraday trading today. RSI at 52.4 indicates neutral strength, while MACD is positive (7.60), suggesting mild bullish sentiment. Current price (460 ₹) is above 50 DMA (453 ₹) but below 200 DMA (537 ₹), reflecting short-term support but medium-term weakness. Volume (12.8 lakh) is higher than the weekly average, adding conviction to price action.
- 💰 Optimal Buy Price: Around 455 ₹ – 465 ₹ (near support zone)
- 📈 Profit-Taking Levels: 480 ₹ – 495 ₹
- 📉 Stop-Loss Protection: 445 ₹
⏳ If already holding SYNGENE today, consider exiting intraday positions if price fails to sustain above 465 ₹ with strong volume. A break below 445 ₹ should trigger an exit to protect capital.
Positive ✅
- Quarterly PAT improved significantly from 68.7 Cr. to 154 Cr.
- Stock trading above 50 DMA
- Low debt-to-equity ratio of 0.04
- DII holding increased by 0.61%
Limitation ⚠️
- Stock trading below 200 DMA (medium-term weakness)
- High P/E of 51.3 compared to industry average (39.8)
- PEG ratio at -6.09 indicates poor growth visibility
- ROCE at 10% and ROE at 7.74% are modest
Company Negative News ❌
- FII holding reduced by 1.05%
- Quarterly profit variation at -11.8% shows earnings volatility
Company Positive News 🌟
- Strong quarterly PAT recovery
- Institutional inflows from DIIs
Industry 🧪
- Industry PE at 39.8 vs SYNGENE PE at 51.3 – stock is overvalued
- Biotech and pharma sector remains defensive but sensitive to R&D outcomes
Conclusion 📌
SYNGENE offers liquidity and short-term support but faces valuation concerns and medium-term weakness. Intraday traders may attempt scalps near support with tight stop-losses. Caution is advised due to earnings volatility and price trading below 200 DMA.
Would you like me to extend this into a swing trade analysis with medium-term entry/exit zones and peer benchmarking against Biocon, Laurus Labs, and Divi’s Lab?